Supramolecular assemblies of rifampicin and cationic bilayers: preparation, characterization and micobactericidal activity

Barbassa, Lilian; Mamizuka, Elsa M.; Carmona-Ribeiro, Ana M.
January 2011
BMC Biotechnology;2011, Vol. 11 Issue 1, p40
Academic Journal
Background: Cationic bilayers based on the inexpensive synthetic lipid dioctadecyldimethylammonium bromide (DODAB) have been useful as carriers for drug delivery, immunoadjuvants for vaccines and active antimicrobial agents. Methods: Rifampicin (RIF) or isoniazid (ISO) interacted with DODAB bilayer fragments (BF) or large vesicles (LV). Dispersions were evaluated by dynamic light-scattering for zeta-average diameter (Dz) and zeta-potential (ζ) analysis; dialysis for determination of drug entrapment efficiency; plating and CFU counting for determination of cell viability of Mycobacterium smegmatis or tuberculosis, minimal bactericidal concentration (MBC) and synergism index for DODAB/drug combinations. Results: DODAB alone killed micobacteria over a range of micromolar concentrations. RIF aggregates in water solution were solubilised by DODAB BF. RIF was incorporated in DODAB bilayers at high percentiles in contrast to the leaky behavior of ISO. Combination DODAB/RIF yielded MBCs of 2/2 and 4/0.007 μg/mL against Mycobacterium smegmatis or Mycobacterium tuberculosis, respectively. Synergism indexes equal to 0.5 or 1.0, indicated synergism against the former and independent action, against the latter species. Conclusions: In vitro, DODAB acted effectively both as micobactericidal agent and carrier for rifampicin. The novel assemblies at reduced doses may become valuable against tuberculosis.


Related Articles

  • Combined drug medium with isoniazid and rifampicin for identification of multi-drug resistant Mycobacterium tuberculosis. Nalini, S.; Lakshmi, R.; Devika, K.; Ravikumar, D.; Ramachandran, R. // Indian Journal of Medical Microbiology;Apr2010, Vol. 28 Issue 2, p162 

    A low-cost method of detecting multi-drug resistant Mycobacterium tuberculosis (MDR-TB) with the possibility of quick adoption in a resource limited setting is urgently required. We conducted a study combining isoniazid and rifampicin in a single LJ medium, to detect MDR-TB strains. Combined and...

  • Gatifloxacin in combination with rifampicin in a murine tuberculosis model. Michael Cynamon; Mary R. Sklaney; Carolyn Shoen // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p429 

    Objectives Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis. Several regimens of gatifloxacin in combination with rifampicin were compared with isoniazid plus rifampicin in a mouse tuberculosis model. Methods C57BL/6 mice were infected...

  • CHIH-DFT determination of the molecular structure infrared spectra, UV spectra and chemical reactivity of three antitubercular compounds: Rifampicin, Isoniazid and Pyrazinamide. Alejandra Favila; Marco Gallo; Daniel Glossman-Mitnik // Journal of Molecular Modeling;Apr2007, Vol. 13 Issue 4, p505 

    Abstract??Three of the most frequent antitubercular agents employed against Mycobacterium tuberculosis are: Rifampicin, Isoniazid and Pyrazinamide. It has been proven that the use of these antitubercular agents together, shortens the treatment period from 12?18?months to 6?months...

  • Experimental and Clinical Studies on Rifacinna - The New Effective Antituberculous Drug (Review). Velichka, Dimova; Ivana, Atanasova; Haruaki, Tomioka; Katsumasa, Sato; Venkata, Reddy; Nadadhur, Geeta; Donna, Daneluzzi; Patisapu, Gangadharam; Todor, Kantardjiev; Arvind, Dhople; Yurii, Feshchenko; Ljudmila, Yashina; Andrei, Toumanov; Zvetana, Zhivkova; Chiaki, Sano // Recent Patents on Anti-Infective Drug Discovery;Jan2010, Vol. 5 Issue 1, p76 

    A new rifamycin derivative 3-(4-cinnamyl-piperazinyl iminomethyl) rifamycin SV (T9) and its sodium salt (T11], Rifacinna�) were in vitro, in vivo, toxicologically and clinically investigated in comparison with rifampicin, rifapentine, rifabutin, rifalazil. Our experiments showed that...

  • Synthesis and Anti-Mycobacterial Activity of N'-[(E)-(Disubstituted- Phenyl)Methylidene]Isonicotino-Hydrazide Derivatives. Junior, Ivan N.; Lourençco, Maria C. S.; Henriques, Maria das Graças M. O.; Ferreira, Barbara; Vasconcelos, Thatyana R. A.; Peralta, Mônica A.; de Oliveira, Pedro S. M.; Wardell, Solange M. S. V.; de Souza, Marcus V. N. // Letters in Drug Design & Discovery;Nov2005, Vol. 2 Issue 7, p563 

    A series of eight N'-[(E)-(disubstituted-phenyl)methylidene]isonicotino-hydrazide derivatives were synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis, and the activity expressed as the minimum inhibitory concentration (MIC) in mg/mL. Four...

  • Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. Shi, Dawei; Li, Liang; Zhao, Yuling; Jia, Qiong; Li, Hui; Coulter, Christopher; Jin, Qi; Zhu, Guofeng // Journal of Antimicrobial Chemotherapy (JAC);Oct2011, Vol. 66 Issue 10, p2240 

    Objectives To determine the association between embB mutations and drug resistance, and to further investigate the mechanism of embB mutations involved in the development of ethambutol and multidrug resistance in Mycobacterium tuberculosis. Methods One hundred and thirty-eight...

  • Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. Zaczek, Anna; Brzostek, Anna; Augustynowicz-Kopec, Ewa; Zwolska, Zofia; Dziadek, Jaroslaw // BMC Microbiology;2009, Vol. 9, p1 

    Background: Rifampin is a first line antituberculosis drug active against bacilli in logarithmic and stationary phase, which interferes with RNA synthesis by binding to bacterial RNA polymerase. Tubercle bacilli achieve resistance to rifampin by accumulation of mutations in a short-81 bp region...

  • Drug Resistance among Pulmonary Tuberculosis Patients in Calabar, Nigeria. Otu, Akaninyene; Umoh, Victor; Habib, Abdulrazak; Ameh, Soter; Lawson, Lovett; Ansa, Victor // Pulmonary Medicine;2013, p1 

    Background. This study aimed to determine the pattern of drug susceptibility to first-line drugs among pulmonary TB patients in two hospitals in Calabar,Nigeria. Methods. This was a descriptive cross-sectional study carried out between February 2011 and April 2012. Sputum samples from...

  • Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis. Brandis, Gerrit; Pietsch, Franziska; Alemayehu, Rahel; Hughes, Diarmaid // Journal of Antimicrobial Chemotherapy (JAC);Mar2015, Vol. 70 Issue 3, p680 

    Objectives Mutations in the β-subunit of RNA polymerase (RNAP), encoded by rpoB, are responsible for rifampicin resistance (RifR). Although many mutations in rpoB can reduce susceptibility, only a few are frequent amongst RifR clinical Mycobacterium tuberculosis (MTB) isolates. It has been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics